Highlights Guardant Health, Inc.

Stocks

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 17:02:26 09/06/2026 BST			5-day change	1st Jan Change
124.32 ^USD	-0.46%		-4.49%	+21.72%

08:38am	Guardant Health Insider Sold Shares Worth $12,629,969, According to a Recent SEC Filing	MT
06-02	Evercore ISI Upgrades Guardant Health to Outperform From In Line, Adjusts PT to $160 From $95	MT

Highlights

05-27	Guardant Health Says Shield Blood Test Included in American Cancer Society Guidelines	MT
05-27	Guardant Health Shield Blood Test Included in Updated American Cancer Society Colorectal Cancer Screening Guidelines	CI
05-27	Blood test added to US colorectal cancer screening options	RE
05-20	Fda approves new Guardant360 liquid cdx, the largest FDA-approved liquid biopsy panel with a 100x expanded footprint	RE
05-20	Guardant Health Announces Fda Approval Of Guardant360 Liquid Cdx, The Largest Fda-Approved Liquid Biopsy Panel	CI
05-07	Guardant Health Q1 Adjusted Loss Narrows, Revenue Rises; Raises Full-Year Revenue Guidance	MT
05-07	Guardant Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	(GH) Guardant Health Expects Full Year 2026 Revenue Range $1.30B - $1.32B, vs. FactSet Est of $1.27B	MT
05-07	Earnings Flash (GH) Guardant Health, Inc. Posts Q1 Adjusted Loss $0.45 per Share, vs. FactSet Est of $-0.45	MT
05-07	Earnings Flash (GH) Guardant Health, Inc. Reports Q1 Revenue $301.7M, vs. FactSet Est of $279.2M	MT
05-07	Guardant Health, Inc. Raises Earnings Guidance for the Full Year 2026	CI
05-04	Guardant Health receives FDA approval for Guardant360® CDx as a companion diagnostic for Arvinas and Pfizer's Veppanu (vepdegestrant) for patients with ER+/Her2- advanced breast cancer with ESR1 mutations	RE
05-04	Guardant Health Announces FDA Approval for Guardant360 Cdx as Companion Diagnostic for Arvinas and Pfizer?S Veppanu for Er+/Her2- Advanced Breast Cancer with Esr1 Mutations	CI
03-30	Guardant Health?s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan	CI
03-24	Guardant Health, Verana Health Collaborate to Advance Precision Medicine	MT
03-24	Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data	CI
03-16	Guardant Health and Manulife Launch Shield Multi-Cancer Detection Test in Hong Kong, Singapore and the Philippines	CI
03-04	Guardant Health Launches Coast-To-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to over 100 Communities Across America	CI
02-19	(GH) Guardant Health Expects Full Year 2026 Revenue Range $1.25B - $1.28B, vs. FactSet Est of $1.25B	MT
02-19	Guardant Health Q4 Adjusted Loss Narrows, Revenue Rises; 2026 Revenue Guidance Set	MT
02-19	Earnings Flash (GH) Guardant Health, Inc. Reports Q4 Revenue $281.3M, vs. FactSet Est of $272.4M	MT
02-19	Earnings Flash (GH) Guardant Health, Inc. Posts Q4 Adjusted Loss $0.50 per Share, vs. FactSet Est of $-0.77	MT
02-19	Guardant Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-19	Guardant Health, Inc. Provides Revenue Guidance for the Fiscal Year 2026	CI
02-18	Guardant Health, Inc. (NasdaqGS:GH) acquired Metasight Diagnostics for approximately $150 million.	CI